Compound Screening Disease Pharma Companies Therapies 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Several of the large pharma companies have recently re-entered the dementia field.
Drug Discovery World
JANUARY 26, 2023
The invasion of Ukraine by Russia was devastating, and its effects were felt throughout pharma as supply chains were disrupted and companies had to pause any operations they were pursuing in those countries, limiting access to medicines in both the near and long term. Despite this, innovation still occurred.
Expert insights. Personalized for you.
130 
Let's personalize your content